On October 12, 2023 SK Biopharmaceuticals, a global biotech focused on the research, development and commercialization of treatments for disorders of the central nervous system (CNS) and oncology, and its U.S. R&D subsidiary, Proteovant Therapeutics, reported data showing that selectively degrading the epigenetic protein p300, with minimal impact on its paralog CBP, results in suppression of androgen receptor signaling and inhibition of tumor growth in a mouse model of androgen receptor (AR) positive prostate cancer (Press release, SK biopharmaceuticals, OCT 12, 2023, View Source [SID1234635896]). Findings are being presented today at the American Association for Cancer Research (AACR) (Free AACR Whitepaper), National Cancer Institute (NCI), and the European Organisation for Research and Treatment (EORTC) AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper) being held in Boston.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The AACR (Free AACR Whitepaper)-NCI-EORTC Conference attracts researchers from around the world to discuss innovations in drug development, target selection, the impact of new discoveries in cellular and molecular biology, and early clinical trials. Today’s presentation is the second in a series of important meetings at which the Proteovant team is sharing research findings that show potential best- and first-in-class protein degraders.

"Although strategies targeting androgen receptor in the treatment of prostate cancer have shown benefits for patients, the reality is that cancer cells ultimately find ways to bypass these therapies, resulting in disease progression," said Zhihua Sui, Ph.D., Chief Scientific Officer of Proteovant Therapeutics. "These data showcase a first-in-class opportunity for therapeutic intervention that suppresses AR signaling through an androgen-independent mechanism."

"We are excited about what our Proteovant team is doing to find novel approaches to treat metastatic castration-resistant prostate cancer," Donghoon Lee, President and CEO of SK Biopharmaceuticals and SK Life Science. "The presentation at the AACR (Free AACR Whitepaper)-NCI-EORTC Conference further demonstrates the value of Proteovant’s work to support our growing pipeline and how it is helping SK Biopharmaceuticals and SK Life Science deliver on our commitment to change the future of CNS and cancer care."

AACR-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper)

Title: Discovery and characterization of a p300-selective degrader demonstrates potent anti-tumor activity in preclinical models of prostate cancer
Presenter: Mike Russell, Ph.D. Director of Biology
Date/Time: Thursday, October 12, 12:30-4:00pm

On October 12, 2023 Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, reported the presentation of preclinical data for FPI-2068, a clinical stage bispecific IgG-based targeted alpha therapy (TAT) designed to deliver actinium-225 to various solid tumors that co-express EGFR-cMET (Press release, Fusion Pharmaceuticals, OCT 12, 2023, View Source,-a-Novel-Targeted-Alpha-Therapy-for-EGFR-cMET-Expressing-Cancers [SID1234635895]). Fusion is jointly developing FPI-2068 with AstraZeneca (LSE/STO/Nasdaq: AZN) under the companies’ multi-asset collaboration agreement. The data are being presented in a poster presentation at the 2023 AACR (Free AACR Whitepaper)-NCI-EORTC AACR-NCI-EORTC (Free AACR-NCI-EORTC Whitepaper) International Conference on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR) (Free ASGCT Whitepaper) (Free EORTC-NCI-AACR Whitepaper), being held October 11-15 in Boston, Massachusetts.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased to share preclinical data demonstrating potent anti-tumor activity and evidence of mechanism of action of FPI-2068. EGFR and cMET are each validated targets, widely expressed in multiple solid tumor types. FPI-2068 combines the potency of an alpha-emitting isotope with the dual antigen targeting capability of the bispecific antibody to deliver a differentiated mechanism of action molecule that we believe has the potential to enhance therapeutic index, said Fusion Pharmaceuticals Chief Scientific Officer Christopher Leamon, Ph.D. "Following the IND clearance obtained earlier this year, we look forward to advancing FPI-2068 into clinical trials given the substantial unmet need for patients with non-small cell lung cancer and other cancer types that are known to co-express EGFR-cMET."

Data from a preclinical study of FPI-2068 are being presented in a poster presentation titled, "FPI-2068: A novel anti-EGFR/cMET, alpha-particle emitting, radioimmunoconjugate for cancer therapy."

In the preclinical study, FPI-2068 demonstrated anti-tumor efficacy in colorectal and lung tumor xenograft mouse models, and single dose administration of FPI-2068 led to prolonged tumor regression. Further, FPI-2068 caused activation of the DNA damage response (DDR) pathway as well as apoptosis, suggesting an inability of the cellular machinery to repair the DNA damage induced by the alpha radiation, consistent with the proposed primary mechanism of action.

These data provide further evidence supporting the clinical development of FPI-2068, which is expected to enter a Phase 1 study for the treatment of solid tumors co-expressing EGFR-cMET. EGFR and cMET are both validated targets that are co-expressed in multiple tumor types, including head and neck squamous cell carcinoma, non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.

Copies of the poster presentation can be found at: View Source following the conclusion of the AACR (Free AACR Whitepaper)-NCI-EORTC Annual Meeting.

About FPI-2068

[225Ac]-FPI-2068 (FPI-2068) is a targeted alpha therapy (TAT) designed to deliver actinium-225 to various solid tumors that co-express EGFR and cMET. EGFR and cMET are validated cancer targets that are co-expressed in multiple tumor types, including head and neck squamous cell carcinoma, non-small cell lung cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.

On October 12, 2023 OmniAb, Inc. (Nasdaq: OABI) reported it will hold a virtual Research & Technology event on Thursday, November 9 beginning at 11:00 a.m. Eastern time (Press release, OmniAb, OCT 12, 2023, View Source;Technology-Virtual-Event-on-November-9/default.aspx [SID1234635894]). The event is expected to last approximately two hours and will include a review of the company’s latest technology offerings and financial results for the three and nine months ended September 30, 2023, which will be announced earlier that morning.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Matt Foehr, Chief Executive Officer, will be joined by members of OmniAb’s senior management team, with a Q&A session to follow management’s presentations.

The webcast and replay, including audio, video and presentation slides, will be available on the Investors portion of OmniAb’s website. Additional information about speakers and their presentations, as well as instructions about how to participate will be announced at a later date.

On October 12, 2023 Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, reported the grant of 80,366 restricted stock units of the company’s common stock and the grant of non-qualified stock options to purchase an aggregate of 140,469 shares of common stock of the company to Howard Horn, its newly appointed Chief Financial Officer and Executive Vice President, Corporate Strategy (Press release, Ultragenyx Pharmaceutical, OCT 12, 2023, View Source [SID1234635893]). The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, as amended, with a grant date of October 9, 2023, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to Mr. Horn being continuously employed by the company as of such vesting dates. The stock options vest over four years, with 25% of the shares underlying the option vesting on the first anniversary of the grant date and the remainder vesting with respect to 1/48th of the shares underlying the options on each monthly anniversary thereafter, subject to Mr. Horn being continuously employed by the company as of such vesting dates. The stock options have a ten-year term and an exercise price of $35.68 per share, equal to the per share closing price of Ultragenyx’s common stock on October 9, 2023.

On October 12, 2023 Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, reported dosing of the first participant in Part 3 of its Phase 1 clinical trial of sudocetaxel zendusortide in patients with advanced ovarian cancer (Press release, Theratechnologies, OCT 12, 2023, View Source [SID1234635892]). Sudocetaxel zendusortide is an investigational, first-in-class peptide-drug conjugate (PDC) that targets the sortilin (SORT1) receptor and expedites the internalization and delivery of a cytotoxic payload directly into cancer cells.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to dose the first of six patients in Part 3 of the Phase 1 trial of sudocetaxel zendusortide with its modified design and dosing regimen," said Christian Marsolais, Ph.D., Senior Vice President and Chief Medical Officer at Theratechnologies. "We look forward to building on the efficacy we’ve observed so far, which is mainly long-term disease stabilization in a number of advanced patients. This first-patient-dosed milestone, thus extends the momentum of our oncology clinical development program."

"Patients with chemo-resistant ovarian cancer are in dire need of effective treatment options," said Ira Winer, M.D., Ph.D., FACOG, Gynecologic Oncology and Phase I multidisciplinary member at Karmanos Cancer Center and trial investigator. "Based on promising preliminary data during the first parts of the Phase 1 trial for sudocetaxel zendusortide, I hope to see both improved tolerability and continued benefit in this patient population as the trial moves onto this next phase."

The announcement follows U.S. Food and Drug Administration (FDA) acceptance on June 2, 2023 of the Company’s amended protocol for the Phase 1 trial. The revised protocol is designed to improve the therapeutic window of sudocetaxel zendusortide and extend its duration of therapy. It includes weekly administration and also narrows the patient population to focus on individuals with high-grade serous ovarian cancer, including high-grade peritoneal or fallopian tube cancer, or high-grade endometrioid cancer – a population in which sudocetaxel zendusortide has demonstrated preliminary efficacy. After establishing the safety of the initial dose in the first six patients, the study aims to enroll a total of 16 patients in Part 3.

Enrollment of the first patient in Part 3 of the trial follows closely upon demonstration of antitumor activity in Parts 1 and 2, as presented at the 2023 annual meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper). Details about the study design, participation criteria and contact information for the five U.S. sites simultaneously enrolling patients can be found at: View Source

About Sudocetaxel Zendusortide (TH1902) and SORT1+ Technology

Sudocetaxel zendusortide is a first-of-its-kind sortilin- (SORT1) targeting PDC, and the first compound to emerge from the SORT1+ TechnologyTM platform. A new chemical entity, sudocetaxel zendusortide employs a cleavable linker to conjugate (attach) a proprietary peptide to docetaxel, a well-established cytotoxic chemotherapeutic agent used to treat many cancers. The FDA granted Fast Track designation to sudocetaxel zendusortide as a single agent for the treatment of all sortilin-positive recurrent advanced solid tumors that are refractory to standard therapy. Sudocetaxel zendusortide is currently being evaluated in a Phase 1 clinical trial.

Theratechnologies has established its SORT1+ TechnologyTM platform as an engine for the development of proprietary PDCs that target SORT1 receptor, which is expressed in multiple tumor types. SORT1 is a "scavenger" receptor that plays a significant role in protein internalization, sorting, and trafficking. Expression of SORT1 is associated with aggressive disease, poor prognosis, and decreased survival. It is estimated that SORT1 is expressed in 40% to 90% of endometrial, ovarian, colorectal, triple-negative breast (TNBC), and pancreatic cancers, making this receptor an attractive target for anticancer drug development.